Related Experiment Video

Updated: Jun 13, 2026

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

[RAAS inhibitors]

Kosuke Minai1, Michihiro Yoshimura

  • 1Department of Internal Medicine, The Jikei University School of Medicine.

Nihon Rinsho. Japanese Journal of Clinical Medicine
|April 15, 2010
PubMed

Insights

Acute coronary syndrome (ACS) involves plaque rupture and blood flow limitation, worsened by the renin-angiotensin-aldosterone system (RAAS). RAAS inhibition, particularly with ACE inhibitors over ARBs, is a key therapeutic strategy for ACS prevention and management.

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology

Context:

  • Acute coronary syndrome (ACS) pathogenesis involves atherosclerotic plaque instability, vasoconstriction, thrombosis, and reduced coronary blood flow.
  • The renin-angiotensin-aldosterone system (RAAS) activation exacerbates ACS conditions.
  • RAAS inhibition represents a crucial therapeutic approach for managing ACS.

Purpose:

  • To evaluate the efficacy of RAAS inhibition in preventing and managing ACS.
  • To compare the effectiveness of Angiotensin-Converting Enzyme (ACE) inhibitors versus Angiotensin II Receptor Blockers (ARBs) in ACS.

Summary:

  • ACS is linked to complex cardiovascular events, with RAAS playing a significant role in its progression.
  • Both ACE inhibitors and ARBs are recognized for their preventative roles in ACS.
  • Evidence suggests ACE inhibitors may offer a slight advantage over ARBs in managing ACS.

Impact:

  • Understanding the role of RAAS in ACS guides therapeutic strategies.
  • Comparative analysis of ACE inhibitors and ARBs informs clinical decision-making for ACS patients.
  • Optimizing RAAS inhibition can lead to improved outcomes in acute coronary syndrome.

Related Concept Videos

Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...